Thursday, 19 Jul 2018

You are here

Good News from ACR17 - Gout

The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

Visit our RheumNow annual meeting site to read our gout content - http://acr17.rheumnow.com/category/gout-crystal/

Specific items:

  • Treatment of hyperuricemia to prevent incident dementia? Some data suggests this. Abstract #2076
  • PossibleGout and OA connection? Human cartilage increases amount and size of MSU crystals. Abstract #2896 http://ow.ly/ABLg30fM2gw
  • Low Uric acid may raise the risk of dementia. Abstract #2080
  • Lower coffee consumption is associated with gout!  Abstract #2066
  • Allopurinol and Febuxostat in lowes the risk of Dementia. Yes you read that right! Jas Singh et al. Abstract #2076
  • Both generic and environmental factors influence the fractional excretion of uric acid Abstract #2061
  • Hyperuricemia is associated with more rapid knee osteoarthritis progression. A&R 2017
  • Tollerizing pegloticase regimen decreases infusion reactions in the TRIPLE study Abstract #1141
  • Gout is under treated people… need to get better  Abstract #1121
  • If you have gout and type II diabetes you have worse gout. More tophi and erosions. Abstract #1118
  • Uncontrolled gout is associated with more heart failure so treat gout effectively. Abstract #1119
  • Risk for CV events lower with the new start probenecid (rather than allopurinol) for older >65 yo patients Abstract #159
  • Dr. Daniel Solomon YR in Review – the DASH diet decrease gout risk https://doi.org/10.1136/bmj.j1794 
  • Diuretics don’t seem to impact hugely on gout treatment objectives in this study Abstract #1129
  • Patients aren’t getting to urate target in gout when treated with allopurinol. Are we using enough? Abstract #166
  • Do we need to change the label ‘gout’ ?!?!? Has negative stereotypes  Abstract #1107
  • Patients with gout have their XOI stopped when they present with AKI. Evidence free zone and makes gout Rx harder. Abstract #1116
  • Gout patients more likely to achieve sUA goal< 6 mg/dL if managed by a rheumatologist. Go team Rheum! Abstract #166
  • Pre-Rx with methylprednisolone superior to HC as prophylaxis for pegloticase w/ greater drug survival  Abstract #213 https://buff.ly/2hKNl3y
  • Double contour sign - earliest sign of uric acid deposition obs in asymptomatic gout pts. Abstract #250 http://ow.ly/YZtb30fDVzZ
  • US of MTP1, distal patellar/triceps tendons, talar + femoral cartilage for MSU in possible gout Abstract #249
  • FORTUNE1: stepwise  Uloric dose comparable to colchicine+Uloric in flare prevention during introductory Rx 
  • Cankinumab reduces CV events, decreases risk of gout & malignancy. Higher infection risk  #YearInReview
  • “Gout patients can have septic arthritis and sickle cell pts can also have gout. Keep this in mind during your nex sickle cell crisis differential diagnoses.”  – J Cush, MD (Rheumatology Roundup). 

Gout Videos

Dr. Jack Cush: When Asymptomatic Hyperuricemia Should Be Treated 

 

Dr. Arthur Kavanaugh: Gout, OA Posters

 

Dr. Ken Saag: Update on Gout Therapy

 

Dr. Janet Pope: Gout Gamechangers 

Disclosures: 
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Immunophysiology of the Gout Attack

Gout may be an ancient disease, with arthritis of the big toe having been described in Egypt in 2,600 BC, but only now are the underlying pathophysiologic events being elucidated and understood.

Obesity, Hypertension and Diuretics Drive Gout Risk

A recent metanalysis suggests that obesity, hypertension and diuretic use are associated with a two-fold increased risk of incident gout.

From a potential of 9923 articles, researchers analyzed 11 studies with data suitable for the meta-analysis.

Gout was 2.24 times more likely to occur in individuals with body mass index ≥ 30 kg/m2 (adjusted relative risk 2.24 (95% confidence interval) 1.76–2.86).

Public Citizen Pressures FDA to Pull Febuxostat

Public Citizen has petitioned the U.S. Food and Drug Administration (FDA) to remove Takeda's drug febuxostat (Uloric) from the market, citing the FDA's own warnings and evidence of serious cardiovascular harms. This follows on a recent FDA safety warning and NEJM paper citing cardiovascular concerns over febuxostat.

Gout Takeaways

The annual EULAR meeting just came to an end today. Rooms are gradually emptying out. People look both content to have updated their knowledge and relieved that four very busy days have concluded. Time to summarize.

Sons of Gout Study

The genetics and heritability of gout has suggested a higher risk in certain families.  A UK cohort study examined the prevalence of gout and monosodium urate (MSU) crystal deposition among those at risk (sons of gout patients) for gout and found a high incidence of hyperuricemia and MSU crystal deposition.